July 18, 2017
Many people who have been living with chronic hepatitis C virus (HCV) also have other health issues, such as type 2 diabetes. In 2015, researchers at the University of Turin, Italy, sought to assess the impact on type 2 diabetes once HCV was cured with modern all-oral HCV treatment, otherwise known as direct-acting antivirals, or DAAs.
Researchers recruited 122 people, most of whom (101) subsequently became cured of HCV. The researchers found that people who were cured underwent "significant improvement" in blood sugar levels. As a result of the decrease in blood sugar levels, in many cases participants' doctors were able to reduce the dose of medicines used to help control blood sugar.
The average profile of participants upon entering the study was as follows:
Participants were monitored for between 24 and 36 weeks (before, during and after treatment cessation).
Researchers divided participants into two groups, as follows:
Researchers found that, on average, blood sugar levels (taken when participants had fasted overnight) fell significantly after cure was achieved.
Furthermore, 37% of cured people were able to reduce their dose of diabetes medicine after cure was achieved. In contrast, among people who were not cured, only 5% were subsequently able to reduce their dose of diabetes medicine.
On average, after being cured, people gained about 3 kilograms in weight. Among those who were not cured, their weight did not change significantly during the study.
Although this was not a randomized clinical trial, the overall results suggest an additional aspect of improved health -- better control of blood sugar -- among some people who were cured of HCV.
Ciancio A, Bosio R, Bo S, et al. Marked improvement of glycaemic control in diabetic patients with chronic hepatitis C achieving sustained virological response after direct-acting antiviral therapy: results of a prospective controlled study. In: Program and abstracts of the International Liver Congress, 19-23 April 2017, Amsterdam, the Netherlands. Poster 221.
|This Week in HIV Research: Diabetes Rate Higher Among People With HIV; and 8-Week Hepatitis C Treatment for HIV/HCV Coinfection|
|Increased Prevalence of Diabetes in HIV-Positive People|
|This Week in HIV Research: Body Mass Index Predicts Diabetes After Year of HIV Treatment, and Streamlining Screening for Neurological Disorders|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|HIV Providers and Advocates Continue to Debate STI Rates in the Era of PrEP and U=U|
|On-Demand PrEP Is Great. Now, What About Women?|
|High Rates of Anal HPV Infection in Gay Men Using PrEP in IPERGAY: The Role of Vaccination|
|Alberta Clinic Explores Long-Term Survival Among HIV-Positive People|
|Potential New Targets to Block HIV Latency|